Dmitry Balyasny’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,827,513
| Closed | -$55.3M | – | 3170 |
|
|
2026
Q1 | $55.3M | Sell |
3,827,513
-1,296,914
| -25% | -$18.6M | 0.07% | 314 |
|
|
2025
Q4 | $73M | Buy |
5,124,427
+3,747,363
| +272% | +$36.8M | 0.09% | 239 |
|
|
2025
Q3 | $10.9M | Buy |
1,377,064
+955,249
| +226% | +$6.8M | 0.01% | 1006 |
|
|
2025
Q2 | $2.42M | Sell |
421,815
-481,419
| -53% | -$3.11M | ﹤0.01% | 1639 |
|
|
2025
Q1 | $7.37M | Buy |
903,234
+53,829
| +6% | +$498K | 0.01% | 1080 |
|
|
2024
Q4 | $8M | Sell |
849,405
-1,065,578
| -56% | -$11.1M | 0.01% | 1060 |
|
|
2024
Q3 | $20.5M | Buy |
1,914,983
+797,883
| +71% | +$8.69M | 0.03% | 617 |
|
|
2024
Q2 | $11.1M | Buy |
+1,117,100
| New | +$11.5M | 0.02% | 838 |
|
|
2024
Q1 | – | Sell |
-1,556,540
| Closed | -$22.1M | – | 2782 |
|
|
2023
Q4 | $22.1M | Sell |
1,556,540
-1,828,892
| -54% | -$20.8M | 0.04% | 562 |
|
|
2023
Q3 | $41.2M | Buy |
3,385,432
+160,399
| +5% | +$2.07M | 0.08% | 323 |
|
|
2023
Q2 | $40.5M | Buy |
3,225,033
+1,106,425
| +52% | +$13.1M | 0.09% | 306 |
|
|
2023
Q1 | $23.5M | Buy |
2,118,608
+118,752
| +6% | +$1.46M | 0.06% | 448 |
|
|
2022
Q4 | $24.4M | Buy |
1,999,856
+314,888
| +19% | +$3.54M | 0.07% | 405 |
|
|
2022
Q3 | $17.6M | Sell |
1,684,968
-468,116
| -22% | -$5.22M | 0.05% | 472 |
|
|
2022
Q2 | $23.1M | Buy |
+2,153,084
| New | +$17.7M | 0.08% | 372 |
|
|
2021
Q2 | – | Sell |
-13,468
| Closed | -$133K | – | 2085 |
|
|
2021
Q1 | $133K | Buy |
+13,468
| New | +$208K | ﹤0.01% | 1612 |
|
|
2020
Q4 | – | Sell |
-22,984
| Closed | -$325K | – | 1452 |
|
|
2020
Q3 | $325K | Buy |
+22,984
| New | +$335K | ﹤0.01% | 1161 |
|
|
2017
Q4 | – | Sell |
-12,900
| Closed | -$195K | – | 2134 |
|
|
2017
Q3 | $195K | Sell |
12,900
-212,414
| -94% | -$2.81M | ﹤0.01% | 1713 |
|
|
2017
Q2 | $2.27M | Buy |
+225,314
| New | +$1.81M | 0.01% | 906 |
|
|
2016
Q3 | – | Sell |
-300,000
| Closed | -$1.64M | – | 1090 |
|
|
2016
Q2 | $1.64M | Buy |
300,000
+109,956
| +58% | +$769K | 0.01% | 703 |
|
|
2016
Q1 | $1.61M | Buy |
+190,044
| New | +$1.35M | 0.01% | 723 |
|
|
2015
Q2 | – | Sell |
-1,436,694
| Closed | -$15.6M | – | 1206 |
|
|
2015
Q1 | $15.6M | Sell |
1,436,694
-48,115
| -3% | -$424K | 0.13% | 246 |
|
|
2014
Q4 | $12.4M | Buy |
+1,484,809
| New | +$10.2M | 0.11% | 256 |
|
|
2014
Q2 | – | Sell |
-194,163
| Closed | -$402K | – | 679 |
|
|
2014
Q1 | $402K | Sell |
194,163
-318,121
| -62% | -$795K | ﹤0.01% | 540 |
|
|
2013
Q4 | $1.2M | Buy |
512,284
+25,499
| +5% | +$56K | 0.02% | 432 |
|
|
2013
Q3 | $1.13M | Buy |
486,785
+86,785
| +22% | +$218K | 0.02% | 517 |
|
|
2013
Q2 | $932K | Buy |
+400,000
| New | +$1.23M | 0.02% | 496 |
|
Other funds holding FOLD
Dmitry Balyasny's FOLD Position: Q2 2026 in Review
Dmitry Balyasny sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 3,827,513 shares — an estimated $55.3M sold.
Dmitry Balyasny first reported a position in FOLD in Q2 2013 and held it in 27 quarters. The position peaked at $73M in Q4 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Dmitry Balyasny reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Dmitry Balyasny sold 3,827,513 Amicus Therapeutics shares in Q2 2026, an estimated $55.3M.
- Dmitry Balyasny first reported a position in Amicus Therapeutics in Q2 2013 and held it in 27 quarters.
- Dmitry Balyasny's Amicus Therapeutics position peaked at $73M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.